Arthritis, Juvenile Clinical Trial
— Joint FitnessOfficial title:
"Joint Fitness": A Double-Armed Controlled Intervention to Assess the Safety and Effectiveness of Resistance Exercise Training on Muscle, Bone, Strength, Symptoms, Quality of Life and Biological Parameters in Children and Young Adults With JIA
Verified date | April 2018 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This research is being done to see if resistance exercise (RE) is safe and has a positive
effect on children and young adults with juvenile idiopathic arthritis (JIA).
JIA is an inflammatory autoimmune disease that can cause severe impairment and disability.
JIA can cause bone loss and decreased muscle strength. The medications used to treat JIA can
also have negative effects on growth and development, strength, and ability to function. RE
is performing movements in a slow and controlled fashion (i.e., no speeding up or using force
in the lifting and lowering of the weight) to lessen force on the joints and tissues. This
study will be using Ren-Ex exercise equipment to perform RE.
Currently the American College of Rheumatology recommends exercise for patients with
arthritis. This exercise includes range of motion exercise to protect joint mobility as well
as low resistance and aerobic exercise (AE) to protect muscle mass, bone health, and fitness.
However, a recent study showed no major differences in functionality or quality of life
between patients who performed AE and those who did not perform AE. There is a need for more
data on the impact of RE on children with JIA. Children and young adults aged 10 to 21 with
juvenile idiopathic arthritis may join.
Status | Completed |
Enrollment | 33 |
Est. completion date | October 2015 |
Est. primary completion date | October 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years to 21 Years |
Eligibility |
Inclusion Criteria: - American College of Rheumatology criteria for polyarticular JIA - Stable medical therapy Exclusion Criteria: - Non-English speaking - Pregnancy - Currently breast feeding - Cognitive impairment as determined by PI (patient is not responsible for making their own health care decisions) |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins University | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Total Body Dual-Emission X-ray Absorptiometry (DEXA) Scan | Total and lean body mass and fat mass will be determined | Baseline and 12 weeks | |
Primary | Change in BMI | Baseline and 12 weeks | ||
Primary | Change in Lower and upper extremity strength testing | Isokinetic strength testing with a Biodex dynamometer to measure peak torque | Baseline and 12 weeks | |
Secondary | Number of Participants with Adverse Events as a Measure of Safety and Tolerability | Baseline and 12 weeks | ||
Secondary | Change in Erythrocyte sedimentation rate (ESR) | Baseline and 12 weeks | ||
Secondary | Change in Quality of Life | Questionnaire administration | Baseline and 12 weeks | |
Secondary | Change in C-reactive protein (CRP) | Baseline and 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05252533 -
A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis
|
Phase 1 | |
Active, not recruiting |
NCT03904459 -
Jaw, Mouth and Bone Health, and Quality of Life in Children With Juvenile Idiopathic Arthritis (JIA)
|
||
Completed |
NCT03311854 -
A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
|
Phase 2 | |
Active, not recruiting |
NCT02277444 -
A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
|
Phase 3 | |
Recruiting |
NCT05083182 -
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
|
Phase 3 | |
Completed |
NCT04133662 -
Sleep & Pain in Juvenile Arthritis
|
N/A |